Drug discovery software company Molegro acquired by CLC bio
CLC bio has announced the acquisition of Molegro as part of its strategy of expanding its bioinformatics offerings beyond next generation sequencing. A specialised software company, Molegro focuses on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor and determination of molecule similarity.
‘We have always had a strong focus on the science behind our software, and joining CLC bio allows us to become part of a strong analysis platform and focus even more on developing the next generation of molecular docking products.’ said René Thomsen, PhD, CEO at Molegro. ‘CLC bio has demonstrated the capability to build an elaborate analysis platform and distribute it internationally, and exactly that competence is the best way to take the features of Molegro's software to the next level.’
Effective immediately, Molegro will become part of CLC bio's organisation at its headquarters in Aarhus, Denmark. The financial terms of the transaction were not disclosed. All existing Molegro customers with an active support and software upgrade contract have been transferred to CLC bio.